CIP
CBAY

Chartwell Investment Partners’s Cymabay Therapeutics CBAY Stock Holding History

Chartwell Investment Partners’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-49,388
Closed -$1.17M – 453
2023
Q4 		$1.17M Buy
49,388
+360
+0.7% +$6.41K 0.04% 343
2023
Q3 		$731K Hold
49,028
– – 0.03% 371
2023
Q2 		$537K Buy
49,028
+2,373
+5% +$22.1K 0.02% 386
2023
Q1 		$406K Buy
+46,655
New +$373K 0.02% 390
2018
Q3 		– Sell
-97,770
Closed -$1.31M – 499
2018
Q2 		$1.31M Buy
97,770
+26,261
+37% +$329K 0.04% 431
2018
Q1 		$929K Buy
+71,509
New +$888K 0.03% 379

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Chartwell Investment Partners's CBAY Position: Q1 2024 in Review

Chartwell Investment Partners sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 49,388 shares — an estimated $1.17M sold.

Chartwell Investment Partners first reported a position in CBAY in Q1 2018 and held it in 6 quarters. The position peaked at $1.31M in Q2 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Chartwell Investment Partners reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Chartwell Investment Partners sold 49,388 Cymabay Therapeutics shares in Q1 2024, an estimated $1.17M.
  • Chartwell Investment Partners first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 6 quarters.
  • Chartwell Investment Partners's Cymabay Therapeutics position peaked at $1.31M in Q2 2018.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Chartwell Investment Partners's 13F filing for Q1 2024, filed 14 May 2024.